Eli Lilly's Mounjaro Sees Strong Demand in India Amid Rising Obesity

Why this matters: The increasing prevalence of obesity and diabetes in India presents a significant market opportunity for pharmaceutical companies like Eli Lilly. Mounjaro's positive reception and strategic pricing could establish it as a leading treatment option, addressing a critical health need in the country.

Market Dynamics:

India's growing affluence has contributed to increased obesity and diabetes rates. Government surveys indicate a rise in overweight and obese individuals, creating a substantial market for weight-loss and diabetes management drugs. Eli Lilly's Mounjaro has gained traction, selling over 81,570 units, reflecting a 60% sales increase between April and May.

Competitive Landscape:

Eli Lilly was the first to introduce its weight-loss drug in India, beating Novo Nordisk. However, Indian drugmakers are racing to produce cheaper versions, intensifying competition. Novo Nordisk is also expected to launch its weight-loss drug, Wegovy, in India next year, further shaping the market dynamics.

Financial Performance:

In Q1 2025, Eli Lilly reported a 45% increase in revenue compared to Q1 2024. Mounjaro sales reached $3.8 billion, more than double the previous year. While marketing and R&D expenses increased, the company saw significant revenue growth in the US, Europe, Japan, and China.

Actionable Takeaways:

Mounjaro is a diabetes and weight-loss drug developed by Eli Lilly.

Due to the increasing rates of obesity and diabetes in the country.

Approximately $150 billion by the early 2030s.

Do you think Eli Lilly will maintain its lead in the Indian market despite increasing competition? Share your thoughts in the comments!

Share this article with others who need to stay ahead of this trend!